BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21623237)

  • 21. Stereotactic body radiation therapy for unbiopsied early-stage lung cancer: a multi-institutional analysis.
    Harkenrider MM; Bertke MH; Dunlap NE
    Am J Clin Oncol; 2014 Aug; 37(4):337-42. PubMed ID: 23660597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
    Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
    Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study.
    Guckenberger M; Heilman K; Wulf J; Mueller G; Beckmann G; Flentje M
    Radiother Oncol; 2007 Dec; 85(3):435-42. PubMed ID: 18053602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
    Parker SM; Siochi RA; Wen S; Mattes MD
    Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer.
    Munoz-Schuffenegger P; Kandel S; Alibhai Z; Hope A; Bezjak A; Sun A; Simeonov A; Cho BCJ; Giuliani M
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):720-727. PubMed ID: 31176537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
    Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
    Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
    Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment.
    Mattonen SA; Palma DA; Johnson C; Louie AV; Landis M; Rodrigues G; Chan I; Etemad-Rezai R; Yeung TP; Senan S; Ward AD
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1121-8. PubMed ID: 26907916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer: Implications for Surveillance.
    Spratt DE; Wu AJ; Adeseye V; Din SU; Shaikh F; Woo KM; Zhang Z; Foster A; Rosenzweig KE; Gewanter R; Huang J; Rimner A
    Clin Lung Cancer; 2016 May; 17(3):177-183.e2. PubMed ID: 26602271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent Cancer Outcomes Following Patient-adapted Robotic Lung SBRT But a Case for Caution in Idiopathic Pulmonary Fibrosis.
    Bahig H; Filion E; Vu T; Roberge D; Lambert L; Bouchard M; Lavoie C; Doucet R; Nadeau DB; Chalaoui J; Campeau MP
    Technol Cancer Res Treat; 2015 Dec; 14(6):667-76. PubMed ID: 24988054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
    Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
    Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung metastases treated with image-guided stereotactic body radiation therapy.
    Baschnagel AM; Mangona VS; Robertson JM; Welsh RJ; Kestin LL; Grills IS
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):236-41. PubMed ID: 23352916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification and Reporting of Late Radiographic Changes After Lung Stereotactic Body Radiotherapy: Proposing a New System.
    Raziee H; Hope A; Faruqi S; Yap ML; Roberts H; Kandel S; Le LW; Brade A; Cho J; Sun A; Bezjak A; Giuliani ME
    Clin Lung Cancer; 2015 Nov; 16(6):e245-51. PubMed ID: 26077096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The feasibility and efficacy of stereotactic body radiotherapy for centrally-located lung tumors.
    Takahashi W; Yamashita H; Omori M; Kitaguchi M; Shibata-Kobayashi S; Sakumi A; Nakagawa K
    Anticancer Res; 2013 Nov; 33(11):4959-64. PubMed ID: 24222136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium.
    Samuels MA; Kandula S; Koru-Sengul T; Bogart JA; Salama JK; Aridgides PD; Gajra A; Lilenbaum RC
    Clin Lung Cancer; 2013 Jul; 14(4):446-51. PubMed ID: 23660522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
    Hamaji M; Chen F; Matsuo Y; Kawaguchi A; Morita S; Ueki N; Sonobe M; Nagata Y; Hiraoka M; Date H
    Ann Thorac Surg; 2015 Apr; 99(4):1122-9. PubMed ID: 25661580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.